access your medical records
Home > Innovation & Research > Research at Avera > Cancer Clinical Trials
To learn more about cancer research and clinical trials at Avera, talk with your cancer care team or call the Avera Cancer Institute Navigation Center at 888-422-1410.
888-422-1410
Cancer clinical trials may open new doors of cancer screening, diagnosis and treatment options for you and your loved ones. Oftentimes, these innovative studies can offer better options for specific circumstances than the current standard of care.
Today’s patients discover new hope for better outcomes and quality of life through clinical trials. Future patients benefit from the lessons learned that lead to improved treatment options and cure rates.
A clinical trial – also known as a clinical research study – is designed to answer specific questions about drugs, vaccines, and medical devices, as well as find new ways of using current treatments for other medical conditions. Clinical drug trials help determine if new treatments are both safe and effective, and are the safest way to find treatments that work.
Before testing can begin in humans through a clinical trial, extensive research must be conducted in animal and human cells. If all testing proves successful and promising, sponsors of the clinical trial must receive Food and Drug Administration (FDA) approval before starting to test through a clinical trial.
Interested in learning more about clinical trials? View our participant information or call the Avera Cancer Institute Navigation Center at 888-422-1410.
Through Avera Cancer Institute’s affiliation with the National Cancer Institute and NRG Oncology, Avera patients benefit from access to a variety of innovative treatment options through clinical trials. View our complete list of oncology studies currently enrolling patients and learn more about our Breast Cancer Collaborative Registry.
Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.
Contact Breast Research Coordinators at (605)322-3295 or email breastresearch@avera.org for more information.
Contact Research Coordinators at (605)322-3086 or (605)322-3295 or (605)322-3018 or (605)322-3295 for more information.
NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Study is for Patients who have persistent unexplained low blood counts, circulating peripheral blasts, or have been recently diagnosed with MDS in the last 6 months and have not received treatment
Contact Research Coordinators at (605)322-3221 or (605)322-3291 for more information.
Contact Research Coordinators at (605)322-3228 or (605)322-3291 for more information.
Contact Research Coordinators at (605)322-7536 or email gynresearch@avera.org for more information.
Contact Research Coordinators at (605)322-3086 or (605)322-3291 for more information.
Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.
S1826: A Phase III, Randomized Study of Nivolumab (OPDIVO) Plus AVD or Brentuximab Vedotin (ADCETRIS) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Contact Research Coordinator at (605)322-3016 for more information.
S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy (Immunotherapy)
Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.
© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.
